blarcamesine
https://www.sciencedirect.com/science/article/pii/S2274580724006083
donanemab
https://jamanetwork.com/journals/jama/fullarticle/2807533
https://pubmed.ncbi.nlm.nih.gov/37459141/
lecanemab
https://www.nejm.org/doi/10.1056/NEJMoa2212948
https://pubmed.ncbi.nlm.nih.gov/36449413/

https://www.anavex.com/investor-material
https://www.anavex.com/post/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-iib-iii-data-in
https://www.anavex.com/post/new-phase-iib-iii-clinical-data-demonstrates-over-three-years-of-continuous-treatment-with-oral-blar
https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2024-fourth-quarter-financial-results-and-provides-business-upda
https://www.anavex.com/_files/ugd/79bcf7_da38b4e0ad4b4ff888363403e3962ef2.pdf
https://clinicaltrials.gov/study/NCT04314934?term=NCT04314934&intr=NCT04314934&rank=1
https://clinicaltrials.gov/study/NCT03887455
https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/evaluation-medicines-step-step#further-consultations-by-day-210-13156
https://investor.lilly.com/news-releases/news-release-details/results-lillys-landmark-phase-3-trial-donanemab-presented
https://seekingalpha.com/article/4748984-playing-the-odds-of-anavex-alzheimers-drug-approval
https://www.youtube.com/watch?v=IYUoANr3cMo
